Abstract
Tamoxifen (TAM, ICI 46,474) is a nonsteroidal antiestrogen of the triphenylethylene family. The clinical use of TAM was first reported in 1971 (Cole et al., 1971), and early clinical trials suggested that TAM was useful in the treatment of metastatic breast cancer (Cole et al., 1971; Ward, 1973; Cole et al., 1972). These studies yielded response rates ranging between 15% and 60% with minimal toxicity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aitken, S., Lippman, M. E.: A simple computer program for quantification and Scatchard analysis of steroid receptor proteins. J. Steroid Biochem. 8, 77–94 (1977)
Breast Cancer Task Force Treatment Committee, National Cancer Institute: Breast cancer: Suggested protocol guidelines for combination chemotherapy trials and for combined modality trials. U.S. Department of Health, Education and Welfare Publication No. (NIH) 77–1192 (1977)
Cole, M. P., Jones, C. T. A., Todd, I. D. H.: A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46,474. Br. J. Cancer 25, 270–275 (1971)
Cole, M. P., Jones, C. T. A., Todd, I. D. H.: The treatment of advanced carcinoma of the breast with the anti-oestrogenic agent tamoxifen (ICI 46,474) — a series of 96 patients. Adv. Antimicrob. Antineoplas. Chemother. 2, 529–531 (1972)
Jensen, E. V., Block, G. E., Smith, S., Kyser, K., De Sombre, E. R.: Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monogr. 34, 55 (1971)
Kiang, D. T., Kennedy, B. J.: Tamoxifen (antiestrogen) therapy in advanced breast cancer. Ann. Intern. Med. 87, 687–690 (1977)
Lehmann, E. H.: Non-parametries: Statistical methods based on ranks, p. 208. San Francisco: Holden-Day Inc. 1975
Lippman, M. E., Huff, K. K.: A demonstration of androgen and estrogen receptors in human breast cancer using a new protamine sulfate assay. Cancer 38, 868–874 (1976)
McGuire, W. L., Carbone, P. P., Sears, M. E., Escher, G. C.: Estrogen receptors in human breast cancer: An overview. In: Estrogen receptors in human breast cancer. McGuire, W. L., Carbone, P. P., Volmer, E. P. (eds.), pp. 1–7. New York: Raven Press 1975
McGuire, W. L., Horwitz, K. B., Pearson, O. H., Segaloff, A.: Current status of estrogen and progesterone receptors in breast cancer. Cancer 39, 2934–2947 (1977)
Morgan, L. R., Schein, P. S., Woolley, P. V., Hoth, D., Macdonald, J., Lippman, M., Posey, L. E., Beazley, R. W.: Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat. Rep. 60, 1437–1443 (1976)
O’Connor, T., Rosenbaum, C., Cardellicchio, D., Cohen, J. L., Stolbach, L.: Estrogen receptor (ER) predicts tamoxifen (Tarn) response in advanced breast cancer (Br). Proc. Ann. Meet. Am. Soc. Clin. Oncol. 19, 374 (1978)
Ward, H. W. C.: Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br. Med. J. 1973 I, 13–14
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Allegra, J.C., Lippman, M.E. (1980). Estrogen Receptor Determination Predicts Response to Tamoxifen Therapy. In: Henningsen, B., Linder, F., Steichele, C. (eds) Endocrine Treatment of Breast Cancer. Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, vol 71. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81406-8_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-81406-8_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81408-2
Online ISBN: 978-3-642-81406-8
eBook Packages: Springer Book Archive